Yubin Kang, M.D. (IMAGE)

University of Oklahoma

Yubin Kang, M.D.

Caption

University of Oklahoma researcher Yubin Kang, M.D., has received $2.9 million in funding from the National Cancer Institute to study whether the drug opaganib, given after CAR T-cell therapy, can help the immune cells fight ultra-high-risk multiple myeloma more effectively.

Credit

University of Oklahoma

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.